Gérard Tobelem
Directeur/Bestuurslid bij OSE IMMUNOTHERAPEUTICS
Profiel
Gérard Tobelem is the founder of Dendrogenix SA, founded in 2018, where he holds the title of Director.
He is currently an Independent Director at OSE Immunotherapeutics SA since 2014.
Dr. Tobelem's former positions include Executive Chairman & Chief Executive Officer at Établissement Français du Sang, Non-Executive Chairman at Theradiag SA from 2012 to 2018, Independent Director at Orphan Synergy Europe-Pharma SA, Director at Louis Dreyfus Foundation, Director at Institut Sup Biotech De Paris, Professor at Université Paris Diderot-Paris 7, and Head-Blood Disorders Department at Lariboisière Hospital.
Actieve functies van Gérard Tobelem
Bedrijven | Functie | Begin |
---|---|---|
OSE IMMUNOTHERAPEUTICS | Directeur/Bestuurslid | 10-04-2014 |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | Oprichter | 01-01-2018 |
Eerdere bekende functies van Gérard Tobelem
Bedrijven | Functie | Einde |
---|---|---|
THERADIAG | Voorzitter | 31-10-2018 |
Institut Sup Biotech De Paris | Directeur/Bestuurslid | 01-07-2017 |
Établissement Français du Sang
Établissement Français du Sang BiotechnologyHealth Technology Établissement Français du Sang collects, prepares, qualifies and distributes blood transfusion products. The company is headquartered in Saint-Denis, France. | Algemeen Directeur | - |
Lariboisière Hospital | Corporate Officer/Principal | - |
Université Paris Diderot-Paris 7 | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
OSE IMMUNOTHERAPEUTICS | Health Technology |
Bedrijven in privébezit | 7 |
---|---|
Theradiag SA
Theradiag SA Medical SpecialtiesHealth Technology Theradiag SA engages in the distribution, development, and manufacturing of in vitro diagnostic and theranostics tests. It operates through the following segments: Theranostics and Diagnostics. The Theranostics segment offers solutions for patients treated with anti-tumour necrosis factor alpha. The Diagnostics segment includes products for anti-immunity, genetics, allergy, infectious disease, drug of abuse, other diagnoses, and instrumentation. The company was founded on December 29, 1986 and is headquartered in Croissy-Beaubourg, France. | Health Technology |
Orphan Synergy Europe-Pharma SA
Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Orphan Synergy Europe-Pharma SA engages in the development of immunotherapy products against late stage cancer. Its products include Tedopi as treatment for lung cancer and Memopi technology which helps the immune system to eliminate malignant cells. The company was founded by Dominique Costantini and Emile Loria on November 17, 2004 and is headquartered in Paris, France. | Health Technology |
Louis Dreyfus Foundation | |
Université Paris Diderot-Paris 7 | Consumer Services |
Lariboisière Hospital | |
Établissement Français du Sang
Établissement Français du Sang BiotechnologyHealth Technology Établissement Français du Sang collects, prepares, qualifies and distributes blood transfusion products. The company is headquartered in Saint-Denis, France. | Health Technology |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | Health Technology |